Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results
Rhea-AI Summary
Embecta (Nasdaq: EMBC) reported first quarter fiscal 2026 financial results on February 5, 2026. The company directs investors to its Investor Relations website for the detailed earnings release and presentation.
Embecta hosted a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on February 5, 2026, with a replay available beginning at 11:00 a.m. ET on February 5, 2026 and archived for one year on the investor relations site.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
EMBC is up 4.03% while peers show mixed moves: KMTS +2.32%, PLSE +7.01%, but BLFS -1.73%, STAA -3.25%, ANGO -0.94%, pointing to a stock-specific earnings reaction rather than a broad sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Q4/FY2025 earnings | Negative | -7.2% | Revenues declined year-over-year and FY2026 guidance framed continued top-line pressure. |
| Aug 08 | Q3 2025 earnings | Positive | +18.5% | Strong revenue growth, higher adjusted EPS, debt reduction and raised FY2025 guidance. |
| May 09 | Q2 2025 earnings | Negative | -10.0% | Revenue declines in U.S. and international markets despite margin improvement and debt paydown. |
| Feb 06 | Q1 2025 earnings | Negative | -2.6% | Revenue contraction across regions while maintaining dividends and executing restructuring plans. |
| Nov 26 | Q4/FY2024 earnings | Positive | +29.8% | Modest revenue growth plus major restructuring and guidance for FY2025 supported a strong rally. |
Earnings headlines have frequently driven sizeable, directionally aligned moves, with both sharp rallies and selloffs tied to reported results and guidance.
Over the last six months, embecta has used earnings and guidance updates to reset expectations. On Nov 26, 2024, Q4 FY2024 results and restructuring news preceded a 29.77% move. Subsequent FY2025 quarters showed mixed revenue trends but ongoing dividends and debt reduction, with reactions ranging from -10% to +18.53%. The Nov 25, 2025 FY2025 results and FY2026 guidance led to a -7.24% move. Today’s Q1 FY2026 release continues this pattern of earnings as the primary catalyst.
Historical Comparison
In the past five earnings releases, EMBC moved about 5.7% on average. Today’s 4.03% pre-earnings move sits within this typical range for financial updates.
Earnings releases trace a path from FY2024 restructuring and guidance, through mixed FY2025 quarterly trends, to updated FY2026 expectations and debt reduction efforts.
Market Pulse Summary
This announcement highlights embecta’s Q1 FY2026 earnings release and access details for the results call and webcast. Recent history shows earnings events have been key catalysts, with moves around prior quarters and full-year updates, including a 29.77% reaction to FY2024 restructuring news. Investors may focus on revenue trajectory, margin trends, and any updates to FY2026 guidance or debt reduction. Future earnings and regulatory filings remain important checkpoints for tracking execution.
AI-generated analysis. Not financial advice.
PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results.
Visit the company’s Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here.
A webcast replay of the call will be available beginning at 11:00 a.m. ET on February 5, 2026, via the embecta investor relations website and archived on the website for one year.
About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
| Contacts: | |
| Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 Contact Media Relations | Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 Contact IR |